Pharmacogenetic Information in Clinical Guidelines: The European Perspective
Publication date
2018-05-01
Authors
Swen, Jesse J.
Nijenhuis, Marga
van Rhenen, Mandy
de Boer-Veger, Nienke J.
Buunk, Anne Marie
Houwink, Elisa J.F.
Mulder, Hans
Rongen, Gerard A.
van Schaik, Ron H.N.
van der Weide, Jan
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx). 1-3 In addition, patients are willing to consent to participate in PGx implementation studies. 4 However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test. 1,2 Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients. 5,6 .
Keywords
Taverne, Pharmacology, Pharmacology (medical)
Citation
Swen, J J, Nijenhuis, M, van Rhenen, M, de Boer-Veger, N J, Buunk, A M, Houwink, E J F, Mulder, H, Rongen, G A, van Schaik, R H N, van der Weide, J, Wilffert, B, Deneer, V H M, Guchelaar, H J & on behalf of the Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP) 2018, 'Pharmacogenetic Information in Clinical Guidelines : The European Perspective', Clinical Pharmacology and Therapeutics, vol. 103, no. 5, pp. 795-801. https://doi.org/10.1002/cpt.1049